MiMedx reports Q4 adjusted EPS 7c, consensus 8c

Reports Q4 revenue $92.91M, consensus $89.42M. Joseph Capper, MiMedx (MDXG) CEO, commented, “We are pleased today to report solid fourth quarter and full year 2024 results. With fourth quarter net sales growth of 7% year-over-year, an Adjusted EBITDA margin of 21% of net sales and yet another strong quarter of free cash flow, our business continued to drive impressive results to close out the year, even in the face of significant disruption caused by the ongoing manipulation of the Medicare reimbursement system in the private office.”